Patents by Inventor Phillip M. Friden
Phillip M. Friden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110281834Abstract: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of a corticosteroid to the skin.Type: ApplicationFiled: November 10, 2009Publication date: November 17, 2011Inventors: Phillip M. Friden, Hyun Kim, Bireswar Chakraborty
-
Publication number: 20100331812Abstract: The present invention describes pharmaceutical formulations and methods suitable for iontophoretic delivery of the formulations to a subject. The formulations comprise an immunomodulator, such as imiquimod, and optionally include various agents and excipients. The formulations can be used as a treatment for skin diseases and conditions such as actinic keratosis, basal cell carcinoma and genital warts. The short term iontophoretic delivery of the formulations results in the creation of a depot effect in the skin of the subject, allowing for a sustained delivery. The shortened delivery time minimizes local side effects at the application site.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Inventors: Phillip M. Friden, Hyun D. Kim, Bireswar Chakraborty
-
Publication number: 20090082713Abstract: The present invention provides methods for the administration of a peptide to a body surface of the patient comprising treating said body surface by microporation and iontophoretically administering the peptide to the body surface. The present invention also encompasses a method of transdermally administering a peptide to the skin of a patient comprising treating the skin with microporation and iontophoretically administering said peptide to the skin. In one embodiment, the body surface or skin is microporated using one or more microneedles.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Inventor: Phillip M. Friden
-
Publication number: 20080261986Abstract: Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface includes a nail plate and/or the skin.Type: ApplicationFiled: March 27, 2008Publication date: October 23, 2008Inventors: Phillip M. Friden, Hyun Kim, Bireswar Chakraborty
-
Publication number: 20070248630Abstract: Pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of methotrexate to at least one target tissue are described and methods for administering methotrexate via iontophoresis.Type: ApplicationFiled: April 19, 2007Publication date: October 25, 2007Inventor: Phillip M. Friden
-
Publication number: 20070248629Abstract: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of acyclovir (ACV) to at least one target tissue. The present invention also provides methods of treating viral infection in at least one target tissue of a patient by iontophoretically delivering a formulation of the invention to the infected target tissues of the patient.Type: ApplicationFiled: April 19, 2007Publication date: October 25, 2007Inventors: PHILLIP M. FRIDEN, BIRESWAR CHAKRABORTY, DINA BERKOVITZ
-
Patent number: 6531573Abstract: Substantially pure peptides containing between 13 and 20 amino acids, inclusive, having the amino acid sequence: R1-R2-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-R15-R16-R17-R18-R19-R20-R21-R22-R23, where R1 is Asp or is absent; R2 is Ser or is absent; R3 is His or is absent; R4 is Ala; R5 is Lys, Gln, Arg, or another basic amino acid; R6 is Arg, Gln, Lys, or another basic amino acid; R7 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R8 is His, Phe, Tyr, Leu, or another hydrophobic amino acid; R9 is Gly, Lys, Arg, or another basic amino acid; R10 is Tyr; R11 is Lys, His, Phe, or another hydrophobic amino acid; R12 is Arg, Gln, Lys, or another basic amino acid; R13 is Lys, Gln, Arg, another basic amino acid, or is absent; R14 is Phe or is absent; R15 is His, Phe, Tyr, Leu, another hydrophobic amino acid, or is absent; R16 is Glu or is absent; R17 is Lys or is absent; R18 is His or is absent; R19 is His or is absent; R20 is Ser or is absent; R21 is His or is absent; R22 is Arg or is absent; and R23 isType: GrantFiled: December 18, 1997Date of Patent: March 11, 2003Assignees: Trustees of Boston University, Periodontix, Inc.Inventors: Frank G. Oppenheim, Tao Xu, F. Donald Roberts, Peter Spacciapoli, Phillip M. Friden
-
Patent number: 6528488Abstract: Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.Type: GrantFiled: January 8, 1999Date of Patent: March 4, 2003Assignee: Demegen, Inc.Inventors: Peter Spacciapoli, David M. Rothstein, Phillip M. Friden
-
Publication number: 20020077282Abstract: Methods for treating cystic fibrosis in a mammal that include administering to the mammal an effective amount of a histatin, a histatin fragment, or a histatin-related peptide are disclosed.Type: ApplicationFiled: January 8, 1999Publication date: June 20, 2002Inventors: PETER SPACCIAPOLI, DAVID M. ROTHSTEIN, PHILLIP M. FRIDEN
-
Publication number: 20020022048Abstract: This invention relates to a completely bioerodable film that adheres to mucosal surfaces and provides sustained pharmaceutical delivery for several weeks.Type: ApplicationFiled: May 25, 2001Publication date: February 21, 2002Inventors: Lev E. Bromberg, Phillip M. Friden
-
Patent number: 6329508Abstract: The present invention pertains to chimeric antibodies that are reactive with transferrin receptors on brain capillary endothelial cells. These antibodies are composed of a variable region, immunologically reactive with the transferrin receptors, that is obtained from one animal source, and a constant region that is derived from an animal source other than the one that provided the variable region. These chimeric antibodies can exist either as isolated entities or as conjugates with a neuropharmaceutical agent for transferal across the blood brain barrier.Type: GrantFiled: July 5, 1994Date of Patent: December 11, 2001Assignee: Alkermes, Inc.Inventor: Phillip M. Friden
-
Patent number: 6153210Abstract: Periodontal disease can be treated by the administration of metal ions, preferably silver ions, to the site where the microorganisms that cause this disease reside. Administration can be to periodontal pockets or adjacent to exposed tooth roots or alveolar bone during periodontal surgical procedures. The metal ions can be administered in polymeric microparticles, deformable films or microparticles embedded within deformable films. The metal ions are particularly microbiocidal to the bacterial pathogens that are the causative agents of periodontal disease.Type: GrantFiled: August 14, 1997Date of Patent: November 28, 2000Assignee: Periodontix, Inc.Inventors: F. Donald Roberts, Phillip M. Friden, Peter Spacciapoli, Eric Nelson
-
Patent number: 6015555Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor and the antibody is a chimera between the variable region from one animal source and the constant region from a different animal source. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.Type: GrantFiled: May 19, 1995Date of Patent: January 18, 2000Assignee: Alkermes, Inc.Inventor: Phillip M. Friden
-
Patent number: 5977307Abstract: The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is reactive with a brain capillary endothelial cell receptor. Other aspects of this invention include a delivery system comprising a ligand reactive with a brain capillary endothelial cell receptor which has formed a fusion protein with a neuropharmaceutical agent. The fusion proteins are also aspects of this invention.Type: GrantFiled: February 13, 1996Date of Patent: November 2, 1999Assignees: Alkermes, Inc., The Regents of the University of CaliforniaInventors: Phillip M. Friden, Ruth M. Starzyk, Sherie L. Morrison, Eun-Chung Park, John P. McGrath
-
Patent number: 5912230Abstract: Histatin-based peptides representing defined portions of the amino acid sequences of naturally occurring human histatins and methods for treatment of fungal or bacterial infection are described. These histatin-based peptides represent the active anti-fungal and anti-bacterial region of naturally occurring human histatins.Type: GrantFiled: March 11, 1998Date of Patent: June 15, 1999Assignees: Periodontix, Inc., Trustees of Boston UniversityInventors: Frank G. Oppenheim, Tao Xu, F. Donald Roberts, Peter Spacciapoli, Phillip M. Friden
-
Patent number: 5885965Abstract: D-amino acid histatins and histatin-based peptides and methods for treatment of fungal or bacterial infection are described. These D-amino acid histatins and histatin-based peptides are longer-acting anti-fungal or anti-bacterial agents than their L-enantiomeric analogues.Type: GrantFiled: March 12, 1998Date of Patent: March 23, 1999Assignees: Periodontix, Inc., Trustees of Boston UniversityInventors: Frank G. Oppenheim, Tao Xu, F. Donald Roberts, Peter Spacciapoli, Phillip M. Friden
-
Patent number: 5833988Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.Type: GrantFiled: April 18, 1996Date of Patent: November 10, 1998Assignee: Alkermes, Inc.Inventor: Phillip M. Friden
-
Patent number: 5672683Abstract: The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is reactive with a brain capillary endothelial cell receptor. Other aspects of this invention include a delivery system comprising a ligand reactive with a brain capillary endothelial cell receptor which has formed a fusion protein with a neuropharmaceutical agent. The fusion proteins are also aspects of this invention.Type: GrantFiled: July 16, 1993Date of Patent: September 30, 1997Assignees: Alkermes, Inc., The Regents of the University of CaliforniaInventors: Phillip M. Friden, Ruth M. Starzyk, Sherie L. Morrison, Eun-Chung Park
-
Patent number: 5527527Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.Type: GrantFiled: January 15, 1993Date of Patent: June 18, 1996Assignee: Alkermes, Inc.Inventor: Phillip M. Friden
-
Patent number: 5182107Abstract: The present invention pertains to a method for delivering a neuropharmaceutical or diagnostic agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutical or diagnostic agent conjugate wherein the antibody is reactive with a transferrin receptor. Other aspects of this invention include a delivery system comprising an antibody reactive with a transferrin receptor linked to a neuropharmaceutical or diagnostic agent and methods for treating hosts afflicted with a disease associated with a neurological disorder.Type: GrantFiled: March 6, 1992Date of Patent: January 26, 1993Assignee: Alkermes, Inc.Inventor: Phillip M. Friden